Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2012

01-07-2012 | Thoracic Oncology

Endoscopic Tumor Length Is an Independent Prognostic Factor in Esophageal Squamous Cell Carcinoma

Authors: Bing-Yen Wang, MD, Chao-Yu Liu, MD, Ching-Hsiung Lin, MD, PhD, Po-Kuei Hsu, MD, Wen-Hu Hsu, MD, Yu-Chung Wu, MD, Ching-Yuan Cheng, MD

Published in: Annals of Surgical Oncology | Issue 7/2012

Login to get access

Abstract

Purpose

To investigate the impact of endoscopic esophageal tumor length on survival for patients with resected esophageal squamous cell carcinoma (ESCC).

Methods

We retrospectively reviewed the clinicopathologic characteristics of 244 ESCC patients who underwent curative resection as the primary treatment at Taipei Veterans General Hospital between January 2000 and November 2010. The endoscopic tumor length was defined as a uniform measurement before completion of the esophagectomy. The impact of endoscopic tumor length on a patient’s overall survival (OS) and disease-free survival (DFS) were assessed. A Cox regression model was used to identify prognostic factors.

Results

The 1-, 3-, and 5-year OS rates were 81.2, 48.2, and 39.6%, respectively, with a median survival time of 18.0 months. The 1-, 3-, and 5-year DFS rates were 66.2, 34.7, and 32.4%, respectively, with a median DFS of 15.0 months. Endoscopic tumor length correlated with pathologic tumor length [Pearson correction (r) = 0.621; P < 0.001] Regression trees analyses suggested an optimum cutoff point of >4 cm to identify patients with decreased long-term survival. In multivariate survival analysis, endoscopic tumor length (more or less than 4 cm) remained an independent prognostic factor for both OS (P = 0.006) and DFS (P = 0.002).

Conclusions

Endoscopic tumor length could have a significant impact on both the OS and DFS of patients with resected ESCC and may provide additional prognostic value to the current tumor, node, and metastasis staging system before patients receive any cancer-specific treatment.
Literature
1.
2.
Thomas P, Doddoli C, Lienne P, et al. Changing patterns and surgical results in adenocarcinoma of the esophagus. Br J Surg. 1997;84:199–25.CrossRef
3.
Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376–85.PubMedCrossRef
4.
Ku GY, Ilson DH. Preoperative therapy for esophageal cancer. Gastroenterol Clin North Am. 2009;38:135–52.PubMedCrossRef
5.
Malaisrie SC, Untch B, Aranha GV, et al. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution. Arch Surg. 2004;139:532–9.PubMedCrossRef
6.
Katrin MS, Bryan HB, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.CrossRef
7.
Rice TW, Adelstein DJ. Precise clinical staging allows treatment modification of patients with esophageal carcinoma. Oncology (Huntingt). 1997;11:58–62.
8.
Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002;95:1434–43.PubMedCrossRef
9.
Gaur P, Sepesi P, Hofstetter WL, et al. A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg. 2010;252:611–7.PubMed
10.
Griffiths EA, Brummell Z, Gorthi G, et al. Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses. J Surg Oncol. 2006;93:258–67.PubMedCrossRef
11.
Bolton WD, Hofstetter WL, Francis AM, et al. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009;138:831–6.PubMedCrossRef
12.
Wang BY, Goan YG, Hsu PK, et al. Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91:887–93.PubMedCrossRef
13.
Yendamuri S, Swisher SG, Correa AM, et al. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009;115:508–16.PubMedCrossRef
14.
Gaur P, Sepesi P, Hofstetter WL, et al. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011;117:63–9.PubMedCrossRef
15.
Edge SB, Byrd DR, Compton CC, et al. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. Chicago: Springer; 2010.
16.
Van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98:547–57.PubMedCrossRef
17.
Hsu WH, Hsu PK, Wang SJ, et al. Positron emission tomography–computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg. 2009;87:1564–8.PubMedCrossRef
18.
Luketich JD, Schauer P, Landreneau R, et al. Minimally invasive surgical staging is superior to endoscopic ultrasound in detecting lymph node metastases in esophageal cancer. J Thorac Cardiovasc Surg. 1997;114:817–23.PubMedCrossRef
19.
Salminen JT, Farkkila MA, Ramo OJ, et al. Endoscopic ultrasonography in the preoperative staging of adenocarcinoma of the distal esophagus and esophagogastric junction. Scand J Gastroenterol. 1999;34:1178–82.PubMedCrossRef
20.
21.
Schlick T, Heintz A, Junginger T. The examiner’s learning effect and its influence on the quality of endoscopic ultrasonography in carcinoma of the esophagus and gastric cardia. Surg Endosc. 1999;13:894–8.PubMedCrossRef
22.
Fockens P, Van den Brande JH, van Dullemen HM, et al. Endosonographic T-staging of esophageal carcinoma: a learning curve. Gastrointest Endosc. 1996;44:58–62.PubMedCrossRef
23.
Lizuka T, Isono K, Kakegawa T, et al. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for registration of esophageal carcinoma cases. Chest. 1989;96:1005–11.CrossRef
24.
Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors: a comparison between the new (1987) and the old editions. Cancer. 1988;61:2310–4.PubMedCrossRef
25.
Bhutani MS, Barde CJ, Markert RJ, et al. Length of esophageal cancer and degree of luminal stenosis during upper endoscopy predict T stage by endoscopic ultrasound. Endoscopy. 2002;34:461–3.PubMedCrossRef
26.
Shinkai M, Niwa Y, Arisawa T, et al. Evaluation of prognosis of squamous cell carcinoma of the esophagus by endoscopic ultrasound. Gut. 2000;47:120–5.PubMedCrossRef
27.
Christopher P, Twine S, Ashley R, et al. Prognostic significance of endoluminal ultrasound-defined disease length and tumor volume (EDTV) for patients with the diagnosis of esophageal cancer. Surg Endosc. 2010;24:870–8.CrossRef
28.
Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.PubMedCrossRef
29.
Altorki NK, Zhou XK, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.PubMedCrossRef
30.
Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.PubMedCrossRef
31.
Roder JD, Busch R, Stein HJ, et al. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg. 1994;81:410–3.PubMedCrossRef
32.
Goldstein NS, Soman A, Sacksner J et al. Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. Am J Clin Pathol. 1999;111:349–51.PubMed
33.
Siu KF, Cheung HC, Wong J. Shrinkage of the esophagus after resection for carcinoma. Ann Surg. 1986;203:173–6.PubMedCrossRef
34.
Bollschwerler E, Baldus SE, Schroder W, et al. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol. 2006;94:355–63.CrossRef
Metadata
Title
Endoscopic Tumor Length Is an Independent Prognostic Factor in Esophageal Squamous Cell Carcinoma
Authors
Bing-Yen Wang, MD
Chao-Yu Liu, MD
Ching-Hsiung Lin, MD, PhD
Po-Kuei Hsu, MD
Wen-Hu Hsu, MD
Yu-Chung Wu, MD
Ching-Yuan Cheng, MD
Publication date
01-07-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2273-y

Other articles of this Issue 7/2012

Annals of Surgical Oncology 7/2012 Go to the issue

Head and Neck Oncology

Risk Factors for Gastric-Tube Dependence Following Tongue Reconstruction

Hepatobiliary Tumors

Salvage Hepatectomy for Local Recurrent Hepatocellular Carcinoma After Ablation Therapy

Healthcare Policy and Outcomes

Tobacco Use Is Associated with Increased Recurrence and Death from Gastric Cancer

Gastrointestinal Oncology

Surgery in Esophageal and Gastric Cancer Patients: What is the Role for Nutrition Support in your Daily Practice?

Gastrointestinal Oncology

Adenocarcinomas of the Esophagogastric Junction Are More Likely to Respond to Preoperative Chemotherapy than Distal Gastric Cancer

Gastrointestinal Oncology

Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients